Park Ha Biological Technology Co., Ltd. Class Action Lawsuit   

Robbins LLP Is Investigating Allegations that Park Ha Biological Technology Co., Ltd. (BYAH) was the subject of a market manipulation and fraudulent promotion scheme and that the Company failed to adequately disclose material risks associated with that activity.

Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) securities between December 27, 2024 and July 8, 2025 (the "Class Period"). The Company traded under ticker symbol "PPH" until October 28, 2025.

The lawsuit alleges that Park Ha was the subject of a market manipulation and fraudulent promotion scheme involving social-media misinformation and individuals impersonating financial professionals, and that the Company failed to adequately disclose risks associated with the alleged scheme.

Park Ha develops and sells skincare and cosmetics products under the “Park Ha” brand and operates franchise beauty stores in China through an online-to-offline (“O2O”) business model.

Investors who suffered losses during the Class Period may have legal rights and should be aware of the September 21, 2026 deadline to seek appointment as lead plaintiff.

Why Was Park Ha Sued?

According to the complaint, Park Ha was allegedly subjected to a pump-and-dump and market manipulation scheme involving social-media-based misinformation and individuals allegedly impersonating financial professionals.

The lawsuit alleges that Park Ha and certain defendants failed to adequately disclose material risks associated with the alleged market manipulation and fraudulent promotion activity.

According to plaintiff, defendants failed to disclose that:

(1) Park Ha was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals;

(2) Park Ha’s public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price;

(3) Park Ha's IPO was intentionally structured with an extremely low public float to enable the manipulation scheme; and

(4) as a result of the foregoing, defendants’ positive statements about PHH’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why Did BYAY Stock Collapse?

This complaint alleges that the collapse of Park Ha's stock followed an artificial price surge created through fraudulent stock promotions conducted immediately after the Company’s initial public offering (“IPO”). Park Ha’s stock price increased from its IPO price of $4.00 to an all-time high of $41.49 on July 7, 2025, despite the absence of any material corporate developments or legitimate business prospects to justify such an enormous spike.

Investigations and public reports have revealed Park Ha’s stock was utilized in a market

manipulation and “pump-and-dump” promotional scheme, with impersonators claiming to be

legitimate financial advisors touting Park Ha's in online forums, chat groups, and social media posts with baseless claims to create a buying frenzy among retail investors.

According to the complaint, Park Ha's stock experienced a dramatic collapse on July 8, 2025. The Company's market value allegedly declined 93% in a single trading day, with the stock closing at $2.99 per share, wiping out more than $1 billion in market capitalization in a single trading session.

Who Is Eligible?

The lawsuit seeks to represent investors who purchased or otherwise acquired Park Ha Biological Technology Co., Ltd. (BYAH) securities during the applicable Class Period. If you purchased Park Ha stock during this period and suffered investment losses, you may have rights under the federal securities laws.

Attorney Advertising.  Past results do not guarantee a similar outcome.  

Send us a message for more information.

Additional Alerts for Shareholders

Pentair plc Investigation

Robbins LLP is Investigating Allegations that the Officers and Directors of Pentair plc (PNR) Violated Securities Laws and Breached Fiduciary Duties to Shareholders Shareholder rights

Read More »
Free!
Skip to content